Eli Lilly and Company reported revenue of $19.8 billion in Q1 2026, reflecting a 56% year-on-year (YOY) increase, driven by strong demand for its incretin-based therapies. Net income reached $7.4 billion, with earnings per share (EPS) of $8.55, indicating significant growth in profitability alongside expanding patient uptake of key medicines. Performance was led by Mounjaro ($8.7 billion) and Zepbound ($4.2 billion), highlighting rapid adoption in diabetes and obesity treatment. The company also raised its full-year 2026 revenue guidance to $82–$85 billion, reflecting continued demand momentum.
Pipeline progress remains focused on expanding access and innovation, including the Phase III programme for orforglipron, an oral GLP-1 receptor agonist, and ongoing studies to broaden indications for existing incretin-based therapies.
The company’s strategy centers on scaling high-impact therapies, expanding manufacturing capacity, and accelerating innovation in metabolic diseases, positioning it to address growing global demand.
The strong growth in incretin-based therapies reflects increasing availability and adoption of more effective treatments for diabetes and obesity, conditions affecting millions globally. Higher revenues driven by these medicines indicate that more patients are gaining access to advanced therapies that offer improved glycaemic control and meaningful weight reduction.
Continued investment in manufacturing and pipeline development, including oral options like orforglipron, could further improve treatment accessibility, convenience, and long-term disease management. As supply expands and new formulations emerge, patients may benefit from broader treatment choices and potentially reduced barriers to access. Additionally, ongoing clinical development and label expansion studies are expected to bring new indications and earlier-line treatment options, supporting better outcomes and earlier intervention for patients with metabolic diseases.
